Canton Biologics Co., Ltd.
Foshan (Shunde District), China
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (2)
○ EMA GMP
○ MHRA GMP
Quick Facts: Canton Biologics Co., Ltd.
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Foshan (Shunde District), China
- Modalities
- Monoclonal Antibody, Bispecific Antibody, Recombinant Protein, Fusion Protein, Plasmid DNA, Lentiviral (process development), Fill-Finish (vial, PFS, lyophilized, BFS)
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Canton Biologics Co., Ltd.
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesMonoclonal Antibody, Bispecific Antibody, Recombinant Protein, Fusion Protein, Plasmid DNA, Lentiviral (process development), Fill-Finish (vial, PFS, lyophilized, BFS)
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (7 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press2 articles
Broad modality coverage (7 modalities)
Recent News 2 articles
After EU withdrawal, catumaxomab ready for phase III trials again under China’s Lintonpharm - BioWorld News
BIOSECURE Act: Pfizer To Lilly - Where Are The Likely Sourcing Gaps? - insights.citeline.com
Frequently Asked Questions About Canton Biologics Co., Ltd.
What is Canton Biologics Co., Ltd.'s CDMO Signal Score?
Canton Biologics Co., Ltd. has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Canton Biologics Co., Ltd. for a manufacturing program?
Use the free AI matchmaker to compare Canton Biologics Co., Ltd. against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Canton Biologics
Guangzhou, China
Monoclonal Antibody, Bispecific Antibody, Recombinant Protein, Fusion Protein, Plasmid DNA, Lentiviral, CAR-T, AAV
AsymBio
Shanghai, China
Monoclonal Antibody, Bispecific Antibody, Recombinant Protein, ADC, Bioconjugates (NDC, RDC, AOC, PDC, BsADC), Plasmid DNA, mRNA, Fill-Finish
Healsun Biopharm (Hangzhou Healsun Biopharm Co., Ltd.)
Hangzhou, China
Monoclonal Antibody, Recombinant Protein, Bispecific Antibody, Fusion Protein, ADC, XDC (ADC, RDC, Bioconjugates), Cell Line Development (CHO)
Chime Biologics
Wuhan, China
Monoclonal Antibody, Bispecific Antibody, Recombinant Protein, Fusion Protein, Biosimilars, ADC (announced/expanding), Drug Product / Fill-Finish
KBI Biopharma
Durham, NC · Boulder, CO
Signal Score: 83.5
Monoclonal Antibody, Recombinant Protein, AAV (analytical only), Plasmid DNA